oncology
Breast Cancer

News in brief: Adjuvant olaparib recommended for early-stage breast cancer; Prof Eva Segelov to lead SerOzNET study; Hospital doctors bullied to discharge patients early

ASCO recommends olaparib for early-stage breast cancer An update to ASCO guidelines recommends one year of adjuvant olaparib for patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The expedited update is based on the results of the OlympiA randomised controlled ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic